EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation

Claudia Pellegrinelli iD, Laura Cavalleri iD, Michela Bravi iD, Paolo Marra iD, Clarissa Valle iD, Lisa Licini iD, Domenico Pinelli iD, Massimo Provenzi iD, Sandro Sironi iD, Lorenzo D'Antiga iD

Pediatric Transplantation · 2026

DOI: 10.1111/petr.70447 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2026. Verfasst von Claudia Pellegrinelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Hauptthemen laut MEDLINE: Hepatoblastoma, Liver Transplantation, Liver Neoplasms. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The management of hepatoblastoma (HB) relies on chemotherapy combined with surgery, either liver resection (LR) or liver transplantation (LT), with reported overall survival (OS) of 80%, cardiac toxicity of 6%, nephrotoxicity of 21%, ototoxicity of 32%–46%. In clinical practice, deviations from protocol‐defined chemotherapy are often required to achieve resectability or bridge to transplantation. We aimed to evaluate the impact of treatment adaptation to surgical timing on OS and toxicity in a selected group of patients referred to a transplantation center.

Methods

We retrospectively analyzed patients with HB treated according to SIOPEL protocols at our center between 2004 and 2022. We collected clinical data, focusing on deviations from protocol‐specified therapy, timing of medical and surgical treatment, OS, treatment‐related toxicities (left ventricular ejection fraction, LVEF< 50%, estimated glomerular filtration rate, eGFR< 90 mL/mL/m 2 , increased hearing threshold of 20–40 dB at 4 kHz).

Results

Forty‐two patients, median age at diagnosis 1.9 years (IQR 0.7–3.5), 16/42 (38.1%) with metastatic disease, 24/42 (57.1%) with vascular involvement were recorded. Additional chemotherapy beyond protocol indications, due to persistent pulmonary metastases, delayed organ availability, or disease progression was administered to 17/20 (85%) who underwent first‐line LT and 10/22 (45%) who underwent LR ( p = 0.007). Death occurred in 3/20 (15%) versus 7/22 (31.8%) ( p = 0.2) respectively. After median follow‐up of 4.5 years (IQR 1.2–6.2) OS is 32/42 (71.4%); cardiotoxicity developed in 1/42 (2.4%), nephrotoxicity in 8/42 (19%), ototoxicity in 9/42 (21.4%).

Conclusions

A large proportion of patients with HB require adaptation of protocol‐specified therapy, especially LT candidates. This favors successful management and is not associated with increased toxicity compared to previous reports.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatoblastomaLiver TransplantationLiver NeoplasmsHumansRetrospective StudiesFemaleMaleInfantChild, PreschoolTreatment OutcomeTime FactorsCombined Modality Therapy

Stichwörter der Autor:innen

childrenhepatoblastomaliver tumorssurvivaltoxicitytransplantation

Autor:innen und Institutionen

  • Pediatric Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Pediatric Hepatology Gastroenterology and Transplantation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
  • Unit of Pathology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
  • Unit of General Surgery 3 and Transplantation, Papa Giovanni XXIII Hospital, Bergamo, Italy.

ORCID-Profile: Claudia Pellegrinelli, Laura Cavalleri, Michela Bravi, Paolo Marra, Clarissa Valle, Lisa Licini, Domenico Pinelli, Massimo Provenzi, Sandro Sironi, Lorenzo D'Antiga

Zitieren

APA

Pellegrinelli, C., Cavalleri, L., Bravi, M., Marra, P., Valle, C., Licini, L., Pinelli, D., Provenzi, M., Sironi, S., & D'Antiga, L. (2026). Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.70447

Vancouver

Pellegrinelli C, Cavalleri L, Bravi M, Marra P, Valle C, Licini L, et al. Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation. Pediatric Transplantation. 2026. doi:10.1111/petr.70447

BibTeX
@article{Pellegrinelli2026,
  author = {Pellegrinelli, Claudia and Cavalleri, Laura and Bravi, Michela and Marra, Paolo and Valle, Clarissa and Licini, Lisa and Pinelli, Domenico and Provenzi, Massimo and Sironi, Sandro and D'Antiga, Lorenzo},
  title = {Treatment Adaptation to Surgical Timing in Pediatric Hepatoblastoma: A 19‐Year Single‐Center Experience With Resection and Liver Transplantation},
  journal = {Pediatric Transplantation},
  year = {2026},
  doi = {10.1111/petr.70447}
}
Kostenlos starten →